C-Rad AB (publ) (CRAD-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.10 Million ≈ $7.65 Million USD) by net assets (Skr347.20 Million ≈ $37.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRAD-B market cap overview for the company's overall valuation and market capitalisation.
C-Rad AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how C-Rad AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
C-Rad AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C-Rad AB (publ) ranked by their cash flow conversion efficiency. Explore C-Rad AB (publ) earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
0.013x |
|
Khonburi Sugar Public Company Limited
BK:KBS
|
0.252x |
|
China Automotive Systems Inc
F:RYV
|
0.075x |
|
Aspen Insurance Holdings Ltd
NYSE:AHL
|
0.087x |
|
Silver Pegasus Acquisition Corp.
NASDAQ:SPEG
|
-0.001x |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
-0.145x |
|
Iris Clothings Limited
NSE:IRISDOREME
|
-0.103x |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
-0.011x |
Annual Cash Flow Conversion Efficiency for C-Rad AB (publ) (2008–2025)
The table below shows the annual cash flow conversion efficiency of C-Rad AB (publ) from 2008 to 2025. View CRAD-B stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr347.20 Million ≈ $37.36 Million |
Skr71.10 Million ≈ $7.65 Million |
0.205x | +121.28% |
| 2024-12-31 | Skr324.99 Million ≈ $34.97 Million |
Skr30.08 Million ≈ $3.24 Million |
0.093x | -21.94% |
| 2023-12-31 | Skr281.60 Million ≈ $30.30 Million |
Skr33.38 Million ≈ $3.59 Million |
0.119x | +196.73% |
| 2022-12-31 | Skr242.54 Million ≈ $26.10 Million |
Skr9.69 Million ≈ $1.04 Million |
0.040x | -49.18% |
| 2021-12-31 | Skr231.09 Million ≈ $24.87 Million |
Skr18.17 Million ≈ $1.96 Million |
0.079x | -14.85% |
| 2020-12-31 | Skr199.79 Million ≈ $21.50 Million |
Skr18.45 Million ≈ $1.99 Million |
0.092x | -51.38% |
| 2019-12-31 | Skr83.33 Million ≈ $8.97 Million |
Skr15.83 Million ≈ $1.70 Million |
0.190x | +285.14% |
| 2018-12-31 | Skr93.64 Million ≈ $10.08 Million |
Skr-9.61 Million ≈ $-1.03 Million |
-0.103x | -82.21% |
| 2017-12-31 | Skr71.41 Million ≈ $7.68 Million |
Skr-4.02 Million ≈ $-432.62K |
-0.056x | +91.09% |
| 2016-12-31 | Skr70.60 Million ≈ $7.60 Million |
Skr-44.62 Million ≈ $-4.80 Million |
-0.632x | -10.29% |
| 2015-12-31 | Skr40.05 Million ≈ $4.31 Million |
Skr-22.95 Million ≈ $-2.47 Million |
-0.573x | -38.13% |
| 2014-12-31 | Skr40.04 Million ≈ $4.31 Million |
Skr-16.61 Million ≈ $-1.79 Million |
-0.415x | +30.97% |
| 2013-12-31 | Skr38.03 Million ≈ $4.09 Million |
Skr-22.86 Million ≈ $-2.46 Million |
-0.601x | +25.17% |
| 2012-12-31 | Skr16.26 Million ≈ $1.75 Million |
Skr-13.06 Million ≈ $-1.41 Million |
-0.803x | -41.62% |
| 2011-12-31 | Skr36.02 Million ≈ $3.88 Million |
Skr-20.43 Million ≈ $-2.20 Million |
-0.567x | -444.26% |
| 2010-12-31 | Skr48.12 Million ≈ $5.18 Million |
Skr-5.01 Million ≈ $-539.60K |
-0.104x | +64.39% |
| 2009-12-31 | Skr29.82 Million ≈ $3.21 Million |
Skr-8.73 Million ≈ $-939.06K |
-0.293x | -2.01% |
| 2008-12-31 | Skr35.05 Million ≈ $3.77 Million |
Skr-10.06 Million ≈ $-1.08 Million |
-0.287x | -- |
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more